Furthermore, the final product should have extended drug stability so that a several ... patients live far from the home infusion provider. Meropenem is a broad-spectrum carbapenem antibiotic ...

Venus Remedies is collaborating with UK-based Infex Therapeutics for the clinical development of MET-X, a ...

Venus Remedies on Tuesday said it has joined hands with UK-based Infex Therapeutics for the development of MET-X, an ...

Results: All solutions of meropenem retained over 90% of the initial drug concentration at five days. The 4-mg/mL solutions retained over 93% of the initial concentration at seven days.

Our Bureau, Bengaluru Tuesday, February 25, 2025, 14:45 Hrs [IST] ...

Venus Remedies has partnered with Infex Therapeutics to develop MET-X, an innovative metallo-beta-lactamase inhibitor, to ...

The vial was being sold for Rs 2,300, which contained 1,000 mg Meropenem and 37.5 mg EDTA. The letter reiterates the procedure for getting approval for a “new drug”. “No new drug shall be ...

Venus Remedies rose 2.15% to Rs 313.65 after the company said it secured exclusive in-licensing rights from UK's Infex Therapeutics to develop and commercialize MET-X in India.